Safety of sildenafil in infants*.
- Samiee-Zafarghandy S 1Division of Pediatric Clinical Pharmacology, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC. 2Duke Clinical Research Institute, Durham, NC. 3Department of Pediatrics, Duke University, Durham, NC. 4Department of Pediatrics, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC. 5Department of Pharmacology and Physiology, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC. 6Intensive Care, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands. 7Department of Paediatric Pharmacology, University Children's Hospital Basel, Switzerland.
- Smith PB
- van den Anker JN
- 2014-03-04
Published in:
- Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. - 2014
Blood Coagulation Disorders
Cardiovascular Diseases
Eye Diseases
Humans
Hypertension, Pulmonary
Infant
Infant, Newborn
Nervous System
Phosphodiesterase 5 Inhibitors
Piperazines
Purines
Sildenafil Citrate
Sulfones
English
OBJECTIVE
In view of the recent U.S. Food and Drug Administration's warning against the use of sildenafil in pediatric patients, we aimed to provide an updated overview of the dosing and safety of sildenafil in infants and to explore the relevance of the present safety concerns to the infant population.
DATA SOURCE
The National Library of Medicine PubMed and Cochrane Database of Systematic Reviews were searched using the following terms: Sildenafil AND (infant OR infants OR newborn OR newborns OR child OR children OR childhood OR pediatric OR pediatrics OR paediatric OR paediatrics).
STUDY SELECTION
Studies presenting original clinical data regarding the dosing, use, or safety of sildenafil in infants with pulmonary hypertension would be included.
DATA EXTRACTION
Of the 49 included studies, case reports and case series were the most common type of publications (n = 25). The identified trials included 625 children, with more than 140 infants. Persistent pulmonary hypertension of the newborn and pulmonary hypertension associated with other conditions were the most common underlying diagnoses.
CONCLUSION
There is currently no evidence of serious adverse event in infants exposed to sildenafil. Present safety concerns regarding the use of sildenafil in pediatric patients should be further explored before being applied to infant population. Sildenafil remains a valuable option for the treatment of pulmonary hypertension in young infants. Prospective studies should be designed in such a way that they include a safety assessment to evaluate potential adverse outcomes of sildenafil therapy in this population.
In view of the recent U.S. Food and Drug Administration's warning against the use of sildenafil in pediatric patients, we aimed to provide an updated overview of the dosing and safety of sildenafil in infants and to explore the relevance of the present safety concerns to the infant population.
DATA SOURCE
The National Library of Medicine PubMed and Cochrane Database of Systematic Reviews were searched using the following terms: Sildenafil AND (infant OR infants OR newborn OR newborns OR child OR children OR childhood OR pediatric OR pediatrics OR paediatric OR paediatrics).
STUDY SELECTION
Studies presenting original clinical data regarding the dosing, use, or safety of sildenafil in infants with pulmonary hypertension would be included.
DATA EXTRACTION
Of the 49 included studies, case reports and case series were the most common type of publications (n = 25). The identified trials included 625 children, with more than 140 infants. Persistent pulmonary hypertension of the newborn and pulmonary hypertension associated with other conditions were the most common underlying diagnoses.
CONCLUSION
There is currently no evidence of serious adverse event in infants exposed to sildenafil. Present safety concerns regarding the use of sildenafil in pediatric patients should be further explored before being applied to infant population. Sildenafil remains a valuable option for the treatment of pulmonary hypertension in young infants. Prospective studies should be designed in such a way that they include a safety assessment to evaluate potential adverse outcomes of sildenafil therapy in this population.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1097/PCC.0000000000000077
- PMID 24583505
- Persistent URL
- https://sonar.ch/global/documents/270085
Statistics
Document views: 56
File downloads:
- Full-text: 0